Today, we’re going to discuss a common scenario we encountered in the clinic which highlights the importance of regular medication review and dialogue between patients and healthcare teams.
Our patient focus has been on bisphosphonate therapy for a staggering 10 years. While bisphosphonates have a role in osteoporosis, they are not generally recommend for such extend periods due to potential complications.
Bisphosphonates slow down bone breakdown cells (osteoclasts), reducing bone loss, but long-term use may increase fracture risks.
Atypical Hip Fracture, Shin et al ScienecDirect 2016
One particularly concerning complication is atypical femoral fractures (AFFs), fractures that can occur in the bone just below the hip joint or the long part of the thigh bone with little or no trauma. Emerging evidence indicates higher occurrence of fractures with prolonged bisphosphonate use, yet they remain relatively rare based on current knowledge.
The choice to continue or discontinue bisphosphonates after 5 years is intricate and should be personalized. Factors such as your initial fracture risk, age, and overall health should be consider.
If you or a loved one have been on bisphosphonates for an extended period, it’s essential to discuss this with your clinical team. Regular reviews of your Individualised treatment can help ensure you are receiving the most optimal, personalised, and up-to-date care possible.
Remember, optimal osteoporosis Individualised treatment often involves more than just medication. A balanced diet rich in calcium and vitamin D, regular weight-bearing and muscle-strengthening exercises, cessation of smoking, and reducing alcohol intake all play significant roles in maintaining bone health.
As always, we’re here to provide expert care and guidance on all things related to osteoporosis. Please don’t hesitate to reach out if you have any concerns or questions. We’re all in this journey together.
